Pfizer seeking US, European OK for Prevenar 13 in Older Adults
This article was originally published in Scrip
Executive Summary
Pfizer wants to sell its 13-valent pneumococcal conjugate vaccine, Prevenar 13, currently used in infants and children to prevent pneumococcal disease caused by Streptococcus pneumoniae, in the US and Europe for use in adults aged 50 or older.